Wilmington Savings Fund Society FSB Trims Stock Holdings in Pfizer Inc. $PFE

Wilmington Savings Fund Society FSB lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.9% in the third quarter, Holdings Channel.com reports. The fund owned 267,838 shares of the biopharmaceutical company’s stock after selling 23,033 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Pfizer were worth $6,825,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Curio Wealth LLC lifted its holdings in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer in the second quarter valued at approximately $30,000. Darwin Wealth Management LLC bought a new position in Pfizer in the second quarter worth approximately $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in shares of Pfizer during the 2nd quarter worth $33,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on PFE. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $27.88.

Pfizer Price Performance

Shares of PFE opened at $25.68 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company’s fifty day moving average price is $25.35 and its 200-day moving average price is $24.99. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The firm has a market capitalization of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.